Journal: Internal Medicine

Article Title: Internal Medicine Year in Review 2022

doi: 10.2169/internalmedicine.2266-23

Figure Lengend Snippet: COVID-19 Related Articles (in Order of Number of Citations).

Article Snippet: 11 , Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G , Hibino Makoto, et al , 4 , 2022 , 61 , 6 , 811 , 819.

Techniques: Control, Comparison, Variant Assay, Infection

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Characteristics of the studies describing the effectiveness and safety of SARS‐CoV‐2 vaccines in inflammatory Bowel Disease (IBD) patients

Article Snippet: Ben Tov et al,2021 , Multicentre, retrospective cohort , Israel , Data from Maccabi Healthcare services between December 2020 and March 2021 including 12,231 IBD patients , Age ≥ 16 years with diagnosis of IBD based on the registry , BNT 162b2 Vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Vaccines, Biomarker Discovery, Binding Assay, Infection, Medications, Enzyme-linked Immunosorbent Assay

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Studies describing seroconversion after SARS‐CoV‐2 vaccination in inflammatory Bowel Disease patients

Article Snippet: Ben Tov et al,2021 , Multicentre, retrospective cohort , Israel , Data from Maccabi Healthcare services between December 2020 and March 2021 including 12,231 IBD patients , Age ≥ 16 years with diagnosis of IBD based on the registry , BNT 162b2 Vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Medications, Vaccines

Journal: Alimentary Pharmacology & Therapeutics

Article Title: Effectiveness and safety of SARS‐CoV‐2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta‐analysis and meta‐regression

doi: 10.1111/apt.16913

Figure Lengend Snippet: Outcomes of studies describing breakthrough CoV‐19 infection in vaccinated inflammatory Bowel Disease (IBD) patients

Article Snippet: Ben Tov et al,2021 , Multicentre, retrospective cohort , Israel , Data from Maccabi Healthcare services between December 2020 and March 2021 including 12,231 IBD patients , Age ≥ 16 years with diagnosis of IBD based on the registry , BNT 162b2 Vaccine , Anti‐receptor binding domain IgG antibodies specific to SARS‐CoV‐2 using the LabCorp Cov2Quant IgG assay.

Techniques: Infection, Comparison, Control

Journal: Nature

Article Title: Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

doi: 10.1038/s41586-021-03739-1

Figure Lengend Snippet: a , Linear correlation of live virus neutralization with SARS-CoV-2 spike PV neutralization for 13 sera from individuals vaccinated with BNT162b2. Linear regression line plotted bounded by 95% CI. b , SARS-CoV-2 PV neutralization by sera from individuals vaccinated with first dose of BNT162b2 ( n = 140) plotted against time since first dose. c , Correlation of SARS-CoV-2 neutralization by sera from individuals vaccinated with BNT162b2 with age. Serum neutralization of spike (D614G) pseudotyped lentiviral particles (ID50) after dose 1 (top, n = 138) or dose 2 (bottom, n = 64) by age. Linear regression line plotted bounded by 95% CI. Bonferroni adjustment was made for multiple comparisons in linear regression. d , ID50 against wild-type (D614G) PV following the second dose of vaccine stratified by age and interval between vaccine doses (3 weeks ( n = 21) and 12 weeks ( n = 43)). GMT ± s.d., Mann–Whitney test. e , Spike mutations in VOCs, along with number of sequences in GISAID database.

Article Snippet: Community participants or healthcare workers who received their first dose of the BNT162b2 vaccine between 14 December 2020 and 10 February 2021 were consecutively recruited at Addenbrooke’s Hospital into the COVID-19 cohort of the NIHR Bioresource.

Techniques: Virus, Neutralization, MANN-WHITNEY

Journal: Nature

Article Title: Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

doi: 10.1038/s41586-021-03739-1

Figure Lengend Snippet: a , Proportion of individuals with detectable serum neutralization of PV after the first dose of Pfizer BNT162b2 vaccine by age. Cut-off for serum neutralization is an inhibitory dilution at which 50% inhibition of infection is achieved (ID50) of 20. Shading, 95% CI. b , Serum neutralization of PV after dose 1 (blue) and dose 2 (red) by age group (<80 years ( n = 79), ≥ 80 years ( n = 59)). c , Neutralization curves for serum from two individuals (ID 4 and ID 8) with lower responses after the first dose (blue) and increased neutralization activity after the second dose (red) of BNT162b2 against pseudovirus expressing wild-type spike protein (D614G). Data shown as mean ± s.e.m. of technical replicates. d , f , Neutralization of SARS-CoV-2 VOCs by sera after dose 1 ( d ) and dose 2 ( f ) of BNT162b2. d , WT, n = 138; B.1.1.7, n = 135; B.1.351, n = 82; P.1, n = 82. f , WT, n = 64; B.1.1.7, n = 53; B.1.351, n = 32; P.1, n = 32. Data shown as GMT ± s.d. e , g , The proportion of participant vaccine sera with neutralization activity against wild-type and mutant spike proteins after dose 1 ( e ) and dose 2 ( g ) (ID50 > 1 in 20 dilution of sera). GMT ± s.d. are representative of two independent experiments each with two technical repeats. Mann–Whitney test was used for unpaired comparisons and Wilcoxon matched-pairs signed rank test for paired comparisons. * P < 0.05, ** P < 0.01, **** P < 0.0001; NS, not significant. HS, human AB serum control.

Article Snippet: Community participants or healthcare workers who received their first dose of the BNT162b2 vaccine between 14 December 2020 and 10 February 2021 were consecutively recruited at Addenbrooke’s Hospital into the COVID-19 cohort of the NIHR Bioresource.

Techniques: Neutralization, Inhibition, Infection, Activity Assay, Expressing, Mutagenesis, MANN-WHITNEY, Control

Journal: Nature

Article Title: Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

doi: 10.1038/s41586-021-03739-1

Figure Lengend Snippet: a , Correlations between serum binding IgG subclass 1–4 antibody responses following vaccination with first dose of BNT162b2 and age in years ( n = 133). b , Correlations between serum binding IgG subclass 1–4 antibody responses following vaccination with first dose of BNT162b2 and serum neutralization using a PV system ( n = 133). c , IgA responses to spike, nucleocapsid and RBD after first dose (light green, n = 133) and second dose (dark green, n = 21) compared to individuals with prior infection (red, n = 18) and negative controls (grey, n = 18) at serum dilution of 1 in 100. d , Correlations between serum binding IgA spike antibody responses following vaccination with first dose of BNT162b2 and serum neutralization using a PV system ( n = 133). Bonferroni adjustment was made for multiple comparisons. Spike proteins tested are Wuhan-1 with D614G (WT). Linear regression lines plotted bounded by 95% CI.

Article Snippet: Community participants or healthcare workers who received their first dose of the BNT162b2 vaccine between 14 December 2020 and 10 February 2021 were consecutively recruited at Addenbrooke’s Hospital into the COVID-19 cohort of the NIHR Bioresource.

Techniques: Binding Assay, Neutralization, Infection

Journal: Nature

Article Title: Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

doi: 10.1038/s41586-021-03739-1

Figure Lengend Snippet: a , b , FluoroSpot analysis by age for IFNγ ( a ) and IL-2 ( b ) T cell responses specific to SARS-CoV-2 spike protein peptide pool following PBMC stimulation. SFU, spot-forming units. Scatter plots show linear correlation line bounded by 95% CI; β , slope/regression coefficient. c , d , FluoroSpot analysis for IFNγ ( c ) and IL-2 ( d ) T cell responses specific to SARS-CoV-2 spike protein peptide pool following stimulation of unexposed PBMCs (stored PBMCs from 2014–2016, n = 20) and PBMCs from vaccinated individuals (<80 IFNγ, n = 46; <80 IL-2, n = 44; ≥80 IFNγ, n = 35; ≥80 IL-2, n = 27) three weeks or more after the first dose of BNT162b2. e , f , FluoroSpot analysis for IFNγ ( e ) and IL-2 ( f ) T cell responses specific to SARS-CoV-2 spike protein peptide pool following stimulation of unexposed PBMCs ( n = 20) and PBMCs from vaccinated individuals three weeks after the first or second dose (first dose: <80 IFNγ, n = 46; <80 IL-2, n = 45; ≥80 IFNγ, n = 31; ≥80 IL-2, n = 19; second dose: <80 IFNγ, n = 15; <80 IL-2, n = 15; ≥80 IFNγ, n = 24; ≥80 IL-2, n = 24). g , h , FluoroSpot analysis for IL-2 ( g ) and IFNγ ( h ) CD4 and CD8 T cell responses specific to SARS-CoV-2 spike protein peptide pool following stimulation after column-based PBMC separation. Mann–Whitney test was used for unpaired comparisons and Wilcoxon matched-pairs signed rank test for paired comparisons. * P < 0.05, *** P < 0.001, **** P < 0.0001; NS, not significant. Error bars, s.d.

Article Snippet: Community participants or healthcare workers who received their first dose of the BNT162b2 vaccine between 14 December 2020 and 10 February 2021 were consecutively recruited at Addenbrooke’s Hospital into the COVID-19 cohort of the NIHR Bioresource.

Techniques: MANN-WHITNEY

Journal: Nature

Article Title: Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

doi: 10.1038/s41586-021-03739-1

Figure Lengend Snippet: n = 101. a , Heatmap of log 2 -transformed fluorescence intensity of 19 autoantibodies; red, positive; blue, negative. b , Age (mean ± s.d.) in years by anti-MPO antibody-positive (red) or -negative (blue) status. c , IgG subclass responses to spike after first dose of BNT162b2 vaccine in individuals with or without anti-MPO antibodies ( n = 100). d , GMT ± s.d of sera from individuals after their first dose of vaccine against wild-type and B.1.1.7 spike mutant SARS-CoV-2 PVs by anti-MPO antibody status. e , Nonparametric rank correlation (Kendall’s tau- b ) of wild-type (WT) PV neutralization, variant (B.1.17) PV neutralization and age (<80 or ≥80 years) against each of 53 cytokines or chemokines. Heatmaps illustrate Tau- b statistic (left) and significance (right, –log 10 FDR).

Article Snippet: Community participants or healthcare workers who received their first dose of the BNT162b2 vaccine between 14 December 2020 and 10 February 2021 were consecutively recruited at Addenbrooke’s Hospital into the COVID-19 cohort of the NIHR Bioresource.

Techniques: Transformation Assay, Fluorescence, Mutagenesis, Neutralization, Variant Assay

Journal: Biomedicines

Article Title: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

doi: 10.3390/biomedicines9111740

Figure Lengend Snippet: Summary of SARS-CoV-2 vaccine strategies with their advantages and limitations.

Article Snippet: 2 , mRNA vaccine , Easy to design, lower risk of accidental infection than viral vaccines , Carrier required to stabilize and pack naked RNA , BNT162b2, mRNA-1273, ARCoV, CureVac (Tübingen, Germany).

Techniques: Immunopeptidomics, Vaccines, Infection, Recombinant, Plasmid Preparation, Control, Virus

Journal: Biomedicines

Article Title: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

doi: 10.3390/biomedicines9111740

Figure Lengend Snippet: Forerunners in clinical trials: possible candidates for future.

Article Snippet: 2 , mRNA vaccine , Easy to design, lower risk of accidental infection than viral vaccines , Carrier required to stabilize and pack naked RNA , BNT162b2, mRNA-1273, ARCoV, CureVac (Tübingen, Germany).

Techniques: Clinical Proteomics, Vaccines, Recombinant, Adjuvant, Modification, Variant Assay, Virus, Binding Assay, In Vitro, Activity Assay, Plasmid Preparation, Formulation

Journal: Biomedicines

Article Title: Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

doi: 10.3390/biomedicines9111740

Figure Lengend Snippet: Vaccines currently in the final phase of clinical trial. Protein subunit vaccines (9) dominate the list followed by mRNA vaccine and recombinant viral vector (3 each). Each of live attenuated, inactivated, virus like particles, and DNA vaccines are in the final phase trial.

Article Snippet: 2 , mRNA vaccine , Easy to design, lower risk of accidental infection than viral vaccines , Carrier required to stabilize and pack naked RNA , BNT162b2, mRNA-1273, ARCoV, CureVac (Tübingen, Germany).

Techniques: Vaccines, Recombinant, Plasmid Preparation, Virus

Journal: Human Vaccines & Immunotherapeutics

Article Title: Emerging trends of research on mRNA vaccines: A co-citation analysis

doi: 10.1080/21645515.2022.2110409

Figure Lengend Snippet: Brief information of clusters in the co-citation network.

Article Snippet: #8 , 50 , Hirotsu, Y (2021) Robust antibody responses to the bnt162b2 mRNA vaccine occur within a week after the first dose in previously infected individuals and after the second dose in uninfected individuals , 116 , - , 0.06 , Dan JM2021Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , SCIENCE.

Techniques: Activity Assay, Activation Assay, Virus, Expressing, Molecular Weight, Polymer, Infection, Wilms Tumor Assay, Bioprocessing, Variant Assay, Vaccines

Journal: Human Vaccines & Immunotherapeutics

Article Title: Emerging trends of research on mRNA vaccines: A co-citation analysis

doi: 10.1080/21645515.2022.2110409

Figure Lengend Snippet: Main citing articles and cited references in each cluster.

Article Snippet: #8 , 50 , Hirotsu, Y (2021) Robust antibody responses to the bnt162b2 mRNA vaccine occur within a week after the first dose in previously infected individuals and after the second dose in uninfected individuals , 116 , - , 0.06 , Dan JM2021Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , SCIENCE.

Techniques: Vaccines, Activity Assay, In Vivo, Immunopeptidomics, Molecular Weight, Polymer, In Vitro, Synthesized, Virus, Infection, Selection, Variant Assay, Expressing, Activation Assay, Modification, Inhibition, Bioprocessing, Wilms Tumor Assay, Quantitative Proteomics, Gene Expression, Generated, RNA Sequencing, Genome Wide, Electroporation, Plasmid Preparation, Control, Comparison